SRTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sensus Healthcare Inc (SRTS) is not a strong buy at this moment for a beginner investor with a long-term focus. The company's financial performance has significantly deteriorated, and there are no immediate positive catalysts or strong trading signals to justify an entry. While analysts maintain a Buy rating, the price target reductions and lack of recent news or influential trading activity suggest caution. The technical indicators and options data do not provide a compelling case for immediate investment.
The MACD is positive and expanding, indicating slight bullish momentum. However, RSI is neutral at 55.061, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 3.81, and resistance is at 4.413. Overall, the technical setup does not strongly favor a buy.
Analyst Scott Henry expects strong revenue growth for the SRT platform in 2026 due to new reimbursement codes. The MACD is positive, suggesting slight bullish momentum.
The company's Q4 2025 financials show a significant decline in revenue (-62.20% YoY), net income (-304.85% YoY), and EPS (-311.11% YoY). Gross margin also dropped by 29.38%. Analysts have reduced price targets, and there are no significant hedge fund, insider, or congressional trades. The stock's technicals and options data do not indicate strong buying interest.
In Q4 2025, revenue dropped to $4.94M (-62.20% YoY), net income fell to -$3.17M (-304.85% YoY), EPS declined to -0.19 (-311.11% YoY), and gross margin decreased to 38.41% (-29.38% YoY). These metrics indicate significant financial underperformance.
Analysts maintain a Buy rating, but price targets have been reduced recently. Alliance Global has a $7.50 target with expectations of growth in 2026, while Maxim lowered its target from $8 to $6 due to weak Q4 results.
